Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

The most common type of renal cell carcinoma (RCC) is clear cell renal cell carcinoma (ccRCC), which has a high metastatic potential. Even though the International Metastatic RCC Database Consortium (IMDC) risk model is conventionally utilized for selection and stratification of patients with metas...

Full description

Bibliographic Details
Main Authors: Marija Kraljević, Inga Marijanović, Maja Barbarić, Emir Sokolović, Merima Bukva, Timur Cerić, Teo Buhovac
Format: Article
Language:English
Published: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-01-01
Series:Biomolecules & Biomedicine
Subjects:
Online Access:https://www.bjbms.org/ojs/index.php/bjbms/article/view/7675
_version_ 1827317511482245120
author Marija Kraljević
Inga Marijanović
Maja Barbarić
Emir Sokolović
Merima Bukva
Timur Cerić
Teo Buhovac
author_facet Marija Kraljević
Inga Marijanović
Maja Barbarić
Emir Sokolović
Merima Bukva
Timur Cerić
Teo Buhovac
author_sort Marija Kraljević
collection DOAJ
description The most common type of renal cell carcinoma (RCC) is clear cell renal cell carcinoma (ccRCC), which has a high metastatic potential. Even though the International Metastatic RCC Database Consortium (IMDC) risk model is conventionally utilized for selection and stratification of patients with metastatic RCC (mRCC), there remains an unmet demand for novel prognostic and predictive markers. The goal of this study was to analyze the expression of Vascular endothelial growth factor (VEGF), Cluster of Differentiation 31 (CD31) to determine microvessel density, and Angiopoietin-1 (Ang-1) in primary kidney tumors, as well as their predictive and prognostic value in patients with metastatic ccRCC (mccRCC) who were treated with first-line sunitinib. The study included 35 mccRCC patients who were treated with first-line sunitinib in period between 2009 and 2019. Immunofluorescence was used to examine biomarker expression in tissue specimens of the primary tumor and surrounding normal kidney tissue. Median disease-free survival (DFS) was longer in patients with negative and low tumor VEGF score than in patients with medium tumor VEGF score (p=0.02). Those with low tumor CD31 expression had a longer median DFS than patients with high tumor CD31 expression (p=0.019). There was no correlation between Ang-1 expression and DFS. The expression of biomarkers in normal kidney tissue was significantly lower than in tumor tissue (p<0.001). In conclusion, higher VEGF scores and greater CD31 expression were associated with longer DFS, but neither of these biomarkers correlated with progression-free survival or overall survival.
first_indexed 2024-04-24T23:38:56Z
format Article
id doaj.art-5c67886500f54f6aa081634be1bb1bd7
institution Directory Open Access Journal
issn 2831-0896
2831-090X
language English
last_indexed 2024-04-24T23:38:56Z
publishDate 2023-01-01
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format Article
series Biomolecules & Biomedicine
spelling doaj.art-5c67886500f54f6aa081634be1bb1bd72024-03-15T13:30:45ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2023-01-0123110.17305/bjbms.2022.7675Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinibMarija Kraljević0https://orcid.org/0000-0001-8058-9908Inga Marijanović1https://orcid.org/0000-0002-8777-9832Maja Barbarić2https://orcid.org/0000-0001-5874-9047Emir Sokolović3Merima Bukva4Timur Cerić5Teo Buhovac6https://orcid.org/0000-0003-4539-4093Oncology Clinic, University Clinical Hospital Mostar, Mostar, Bosnia and HerzegovinaOncology Clinic, University Clinical Hospital Mostar, Mostar, Bosnia and HerzegovinaLaboratory of Morphology, Department of Histology and Embryology, School of Medicine, University of Mostar, Mostar, Bosnia and HerzegovinaOncology Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and HerzegovinaAssociation of Basic Medical Sciences of FBIH, Sarajevo, Bosnia and HerzegovinaOncology Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and HerzegovinaOncology Clinic, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina The most common type of renal cell carcinoma (RCC) is clear cell renal cell carcinoma (ccRCC), which has a high metastatic potential. Even though the International Metastatic RCC Database Consortium (IMDC) risk model is conventionally utilized for selection and stratification of patients with metastatic RCC (mRCC), there remains an unmet demand for novel prognostic and predictive markers. The goal of this study was to analyze the expression of Vascular endothelial growth factor (VEGF), Cluster of Differentiation 31 (CD31) to determine microvessel density, and Angiopoietin-1 (Ang-1) in primary kidney tumors, as well as their predictive and prognostic value in patients with metastatic ccRCC (mccRCC) who were treated with first-line sunitinib. The study included 35 mccRCC patients who were treated with first-line sunitinib in period between 2009 and 2019. Immunofluorescence was used to examine biomarker expression in tissue specimens of the primary tumor and surrounding normal kidney tissue. Median disease-free survival (DFS) was longer in patients with negative and low tumor VEGF score than in patients with medium tumor VEGF score (p=0.02). Those with low tumor CD31 expression had a longer median DFS than patients with high tumor CD31 expression (p=0.019). There was no correlation between Ang-1 expression and DFS. The expression of biomarkers in normal kidney tissue was significantly lower than in tumor tissue (p<0.001). In conclusion, higher VEGF scores and greater CD31 expression were associated with longer DFS, but neither of these biomarkers correlated with progression-free survival or overall survival. https://www.bjbms.org/ojs/index.php/bjbms/article/view/7675CarcinomaRenal CellSunitinibVEGF-AAng-1PECAM-1
spellingShingle Marija Kraljević
Inga Marijanović
Maja Barbarić
Emir Sokolović
Merima Bukva
Timur Cerić
Teo Buhovac
Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
Biomolecules & Biomedicine
Carcinoma
Renal Cell
Sunitinib
VEGF-A
Ang-1
PECAM-1
title Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
title_full Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
title_fullStr Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
title_full_unstemmed Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
title_short Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
title_sort prognostic and predictive significance of vegf cd31 and ang 1 in patients with metastatic clear cell renal cell carcinoma treated with first line sunitinib
topic Carcinoma
Renal Cell
Sunitinib
VEGF-A
Ang-1
PECAM-1
url https://www.bjbms.org/ojs/index.php/bjbms/article/view/7675
work_keys_str_mv AT marijakraljevic prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib
AT ingamarijanovic prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib
AT majabarbaric prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib
AT emirsokolovic prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib
AT merimabukva prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib
AT timurceric prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib
AT teobuhovac prognosticandpredictivesignificanceofvegfcd31andang1inpatientswithmetastaticclearcellrenalcellcarcinomatreatedwithfirstlinesunitinib